IBD: Disease activity following induction therapy with biologics predicts short-term outcomes in Crohn's disease and ulcerative colitis

Currently, in the clinical treatment of Crohn's disease (CD) and ulcerative colitis (UC), researchers have identified secondary loss of patient response to biological therapy as a serious clinical challenge
.

To date, no single marker has been found to be effective as a prognostic indicator of response to biological therapy in CD and UC patients

Currently, in the clinical treatment of Crohn's disease (CD) and ulcerative colitis (UC), researchers have identified secondary loss of patient response to biological therapy as a serious clinical challenge

 

RESULTS: Among UC patients with disease activity after induction therapy, compared with UC patients without disease activity, there was a 3.
9-fold increased risk of surgery or steroid therapy during the 6-month follow-up period (95% CI, 1.
6-9.
3), while the risk of needing surgery or steroid therapy was 3.
6-fold higher in CD patients (95% CI, 1.
7-7.
6)
.

Moreover, the overall treatment effect of patients with different types of inflammatory bowel disease was significantly positively correlated with short-term disease activity

 

This study demonstrates that positive treatment response to biologic therapy following induction therapy (as measured by C-reactive protein and clinical scores) predicts better short-term outcomes in CD and UC patients and is also associated with longer-term disease outcomes
.

This study demonstrates that positive treatment response to biologic therapy following induction therapy (as measured by C-reactive protein and clinical scores) predicts better short-term outcomes in CD and UC patients and is also associated with longer-term disease outcomes
.

Original source:

Michael Due Larsen.

Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Leave a Comment here